Charles River Laboratories International Balance Sheet Health
Financial Health criteria checks 4/6
Charles River Laboratories International has a total shareholder equity of $3.8B and total debt of $2.3B, which brings its debt-to-equity ratio to 60.1%. Its total assets and total liabilities are $8.0B and $4.2B respectively. Charles River Laboratories International's EBIT is $598.0M making its interest coverage ratio 4.9. It has cash and short-term investments of $210.2M.
Key information
60.1%
Debt to equity ratio
US$2.30b
Debt
| Interest coverage ratio | 4.9x |
| Cash | US$210.17m |
| Equity | US$3.83b |
| Total liabilities | US$4.18b |
| Total assets | US$8.00b |
Recent financial health updates
We Think Charles River Laboratories International (NYSE:CRL) Is Taking Some Risk With Its Debt
Jan 26
Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 26Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt
Jul 26Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Recent updates
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Could Be 39% Below Their Intrinsic Value Estimate
Feb 10Charles River Laboratories: Retained Earnings, ROE, And Debt Management Will Shape Its Future Amid Weak Demand
Feb 01We Think Charles River Laboratories International (NYSE:CRL) Is Taking Some Risk With Its Debt
Jan 26Charles River Labs: Near A Fundamental Trough, Growth Should Reignite Again
Jan 17What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You
Jan 10Is There Now An Opportunity In Charles River Laboratories International, Inc. (NYSE:CRL)?
Dec 11Charles River Laboratories: Not The Right Time To Own At This Point In The Cycle
Nov 19Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 26What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You
Oct 11Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching
Sep 10US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results
Aug 10Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
Aug 10Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt
Jul 26Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)
Jul 11Charles River Laboratories: Fair Valuation Against Fundamentals
May 31What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?
May 25Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?
Apr 27Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
Apr 11Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues
Feb 21Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Nov 26Charles River: Q3 Points To Ongoing Deterioration
Nov 09Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
Oct 06Charles River Laboratories: Very Attractive After The Pullback
Jul 26Financial Position Analysis
Short Term Liabilities: CRL's short term assets ($1.5B) exceed its short term liabilities ($1.0B).
Long Term Liabilities: CRL's short term assets ($1.5B) do not cover its long term liabilities ($3.2B).
Debt to Equity History and Analysis
Debt Level: CRL's net debt to equity ratio (54.6%) is considered high.
Reducing Debt: CRL's debt to equity ratio has reduced from 120.6% to 60.1% over the past 5 years.
Debt Coverage: CRL's debt is well covered by operating cash flow (34.6%).
Interest Coverage: CRL's interest payments on its debt are well covered by EBIT (4.9x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 09:22 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/28 |
| Annual Earnings | 2023/12/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Charles River Laboratories International, Inc. is covered by 46 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Gregory Bolan | Avondale Partners |
| Eric Coldwell | Baird |